Mitoxantrone

證據等級: L5

預測適應症: 8 個

Mitoxantrone: From Hematologic Malignancies to Upper Aerodigestive Tract Neoplasm

One-Sentence Summary

Mitoxantrone is an anthracenedione antineoplastic agent classically used for acute leukemias, non-Hodgkin’s lymphoma, and metastatic breast cancer; its liposomal formulation (PLM60) has been approved in China for relapsed/refractory peripheral T-cell lymphoma (PTCL). The TxGNN model predicts it may be effective for Upper Aerodigestive Tract Neoplasm — a category encompassing nasopharyngeal carcinoma, salivary gland cancers, and NK/T-cell lymphomas of the head and neck region — with 1 active Phase 3 clinical trial and 20 publications currently supporting this direction. Evidence currently sits at L2, supported by completed Phase 1b data and multiple historical Phase 2 trials, with a growing pipeline of Phase 2/3 studies using the newer liposomal formulation.

Quick Overview

Item	Content
Original Indication	Not registered in the Philippines; globally established for leukemia, non-Hodgkin’s lymphoma, and breast cancer
Predicted New Indication	Upper Aerodigestive Tract Neoplasm
TxGNN Prediction Score	99.78%
Evidence Level	L2
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available from the current Philippines FDA or DrugBank query. Based on published literature, Mitoxantrone is an anthracenedione compound that exerts its antitumor effects primarily by inhibiting DNA Topoisomerase II (Topo II) and intercalating directly into DNA, causing double-strand breaks and halting cell replication. It shares structural and mechanistic similarities with doxorubicin, and its primary elimination is hepatic (only ~7% renal excretion), giving it a terminal half-life of approximately 40–70 hours. Its liposomal reformulation (PLM60) exploits the Enhanced Permeability and Retention (EPR) effect to increase drug concentration in solid tumors while reducing systemic cardiotoxicity.

The connection to upper aerodigestive tract neoplasms is mechanistically grounded: Topo II is highly overexpressed in head and neck squamous cell carcinoma (HNSCC) and in extranodal NK/T-cell lymphomas — the predominant lymphoma subtype arising in the upper aerodigestive tract. This overexpression creates a selective vulnerability to Topo II inhibitors like Mitoxantrone. Historical Phase 2 studies conducted between 1984 and 2002 consistently demonstrated partial responses and disease stabilization in nasopharyngeal carcinoma, salivary gland cancers, and head and neck SCC when Mitoxantrone was used as single-agent or in combination regimens.

More recently, the field has been reinvigorated by PLM60. A completed multicenter Phase 1b study (NCT04902027; PMID 39952083, published 2025 in Oral Oncology) enrolled 45 patients with recurrent/metastatic HNSCC and established both a favorable safety profile and preliminary efficacy signals — providing the most direct modern evidence and forming the basis for at least four currently active or planned Phase 2/3 trials. The TxGNN model’s high-confidence prediction (99.78%) therefore aligns well with a biological rationale supported by three decades of incremental clinical data.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06953739	Phase 3	Not Yet Recruiting	60	Randomized comparison of P-GEMD (containing Mitoxantrone) vs. P-Gemox for untreated early-stage non-upper aerodigestive or advanced-stage extranodal NK/T-cell lymphoma — a critical aerodigestive subtype; Phase 3 design, though sample size of 60 is modest

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39952083	2025	Phase 1b	Oral Oncology	PLM60 (liposomal Mitoxantrone) in 45 patients with recurrent/metastatic HNSCC; established safety profile and preliminary efficacy signals — the most current and directly relevant completed study
12045460	2002	Phase 2	Anti-Cancer Drugs	Mitoxantrone + cisplatin in 14 patients with locally recurrent/metastatic salivary gland carcinomas; assessed efficacy and tolerability in a difficult-to-treat aerodigestive subtype
11290867	2001	Phase 2	Anti-Cancer Drugs	Ifosfamide + Mitoxantrone (12 mg/m²) in 22 patients with recurrent/metastatic head and neck SCC; tolerable toxicity profile with disease control observed
8922205	1996	Phase 2	Annals of Oncology	EORTC study of Mitoxantrone in adenoid cystic carcinoma of the head and neck; initiated based on prior case report activity — important negative/stabilization data from a cooperative group
1735075	1992	PK/PD Study	Cancer	PK/PD characterization of Mitoxantrone (12–14 mg/m²) in 15 patients with advanced nasopharyngeal carcinoma; described three-compartment model with terminal half-life ~71 hours, supporting dosing rationale for aerodigestive cancers
11269736	2001	Phase 1	Cancer Chemotherapy and Pharmacology	Phase I study of Mitoxantrone + raltitrexed + levofolinic acid + 5-FU in advanced solid tumors including head and neck and colorectal cancers; demonstrated tolerability of Mitoxantrone-containing combinations
36070368	2022	Translational Study	Science Translational Medicine	Pharmacogenomic profiling of 56 HNSCC patient-derived cells identified drug sensitivities; Mitoxantrone emerged as a candidate for precision oncology approaches in HNSCC
3512224	1986	Review	Drug Intelligence & Clinical Pharmacy	Comprehensive early review of Mitoxantrone; explicitly notes “some activity in head and neck cancer” alongside leukemias and lymphoma, establishing the historical basis for this indication
1985750	1991	Prospective Cohort	Cancer	Prospective treatment of 20 patients with anaplastic thyroid carcinoma using chemotherapy + radiation; Mitoxantrone (14 mg/m²) used in older patients (≥65 years) as an alternative to doxorubicin, demonstrating tolerability in a high-risk aerodigestive subtype
31324333	2019	Systematic Review	Bulletin du Cancer	Systematic review of systemic treatments for metastatic/locally recurrent adenoid cystic carcinoma of the head and neck; contextualizes the role of chemotherapy including Mitoxantrone-containing regimens

Philippines Market Information

Mitoxantrone currently has no registered products with the Philippine FDA (FDA Philippines). There are 0 active licenses or marketing authorizations on record.

This drug is not commercially available through the standard Philippines pharmaceutical market. Any clinical use would require compassionate use authorization, hospital importation, or participation in a clinical trial.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Anthracenedione class (Topoisomerase II inhibitor); structurally and mechanistically related to anthracyclines (doxorubicin class)
Myelosuppression Risk	High — Neutropenia is the primary dose-limiting toxicity; thrombocytopenia and anemia also expected. Nadir typically at days 10–14
Emetogenicity Classification	Low to Moderate — Generally well-tolerated; lower emetogenic potential than doxorubicin
Monitoring Items	CBC with differential (baseline and each cycle), LVEF by echocardiography or MUGA (cumulative cardiac toxicity monitoring mandatory — lifetime cumulative dose limit applies), liver function tests, serum creatinine
Handling Protection	Required — Must follow cytotoxic drug handling regulations; causes characteristic blue-green discoloration of urine, sclera, and skin (useful indicator of exposure); standard closed-system transfer device recommended

Safety Considerations

Please refer to the package insert for safety information.

Note: Philippine FDA package insert data was not available for this query. Formal safety assessment (warnings, contraindications, drug interactions) should be obtained directly from the originator’s prescribing information or the WHO drug monograph before clinical use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN model prediction is strongly supported by biological plausibility (Topo II overexpression in upper aerodigestive tumors), three decades of Phase 2 trial history, a completed Phase 1b trial with the modern liposomal formulation (PLM60; NCT04902027, n=45, published 2025), and an active and growing Phase 2/3 clinical development pipeline — making this a credible and actionable repurposing candidate rather than a speculative one. However, no completed Phase 3 randomized trial exists yet, and the drug is not registered in the Philippines, requiring specific regulatory and logistical pathways.

To proceed, the following is needed:

MOA and safety data: Obtain the full DrugBank monograph and WHO package insert to complete the mechanism of action analysis and formal safety profiling (warnings, contraindications, drug-drug interactions)
Philippines regulatory pathway: Initiate compassionate use or expanded access application with FDA Philippines, or pursue enrollment in an ongoing international trial (e.g., NCT06472713 or NCT07070479)
PLM60 access assessment: Clarify whether PLM60 (the liposomal formulation, approved in China for PTCL) can be sourced under compassionate use, as it has a superior safety profile to conventional Mitoxantrone for solid tumor use
Subtype-specific patient selection: Define which upper aerodigestive subtype(s) to target (HNSCC vs. NK/T-cell lymphoma vs. nasopharyngeal carcinoma) since evidence strength and trial infrastructure differ significantly across subtypes
Cardiac monitoring protocol: Establish baseline LVEF and cumulative dose tracking plan before any clinical use, given mandatory cardiotoxicity surveillance requirements for all Mitoxantrone-containing regimens
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.